INVION LIMITED — Capital/Financing Update 2015

May 18, 2015

ASX / MEDIA ANNOUNCEMENT

==> picture [161 x 76] intentionally omitted <==

EVP R&D DR MITCHELL GLASS, AND DR MARIO CASTRO OF WASHINGTON UNIVERSITY

DISCUSS WITH BRR MEDIA THE INV102 (ORAL NADOLOL) DATA PRESENTED TO

AMERICAN THORACIC SOCIETY MEETING IN DENVER, COLORADO

Brisbane, Australia and Delaware, United States, 19 May 2015: Australian respiratory technology company Invion Limited (ASX: IVX) is delighted to invite investors to listen to Invion’s Dr Mitchell Glass and Dr Mario Castro of Washington University discuss INV102 (oral nadolol) data that has been presented to international medical experts at a prestigious US pulmonary conference, the American Thoracic Society (ATS) Meeting.

In this audiocast, Drs Glass and Castro discuss:

• Invion’s fully recruited phase 2 trial of INV102 (oral nadolol) in patients with chronic cough, and how can nadolol potentially help smokers to quit

• Why this trial important for other respiratory diseases like asthma and COPD

• Next steps for this clinical program

To access the audiocast, please visit this link: http://www.brrmedia.com/event/138657

---

About Invion Limited

Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol) a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the - build-up of mucus in the lungs. INV103 (ala Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA.

FOR MORE INFORMATION CONTACT

Managing Director and CEO: Dr Greg Collier. P: 07 3295 0500 greg.collier@inviongroup.com

Invion Limited ABN 76 094 730 417

GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com